Skip to main content
Download PDF

Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Respiratory Research volume 20, Article number: 18 (2019) Cite this article

The Original Article was published on 20 November 2018

Correction to: Respir Res

https://doi.org/10.1186/s12931-018-0916-7

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.

  • Reference 24 needs to be amended to 25

  • The 12-week study needs to be corrected to 8-week study

Corrected text:

This study is the first to compare two LAMA/LABA dual therapies using direct head-to-head data from a randomized, 8-week study [25], which is the most reliable set of data to include within a cost-effectiveness model [25].

Reference

  1. Driessen, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respir Res. 2018;19:224. https://doi.org/10.1186/s12931-018-0916-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Value Evidence and Outcomes, GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK

    M. T. Driessen & Y. Asukai

  2. ICON Health Economics, ICON plc, Abingdon, UK

    J. Whalen & B. Seewoodharry Buguth

  3. Departamento de Evaluación de Medicamentos, GSK, Tres Cantos, Madrid, Spain

    L. A. Vallejo-Aparicio

  4. Global Respiratory Franchise, GSK, Brentford, Middlesex, UK

    I. P. Naya

  5. Hospital de Alta Resolución de Loja, Granada, Spain

    B. Alcázar-Navarrete

  6. Pneumology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain

    M. Miravitlles

  7. Hospital Universitario La Paz-IdiPAZ, Madrid, Spain

    F. García-Río

  8. ICON Health Economics, ICON, Toronto, ON, Canada

    N. A. Risebrough

Authors
  1. M. T. Driessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Whalen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Seewoodharry Buguth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. A. Vallejo-Aparicio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. P. Naya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. Asukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Alcázar-Navarrete
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Miravitlles
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. García-Río
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N. A. Risebrough
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Asukai.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Driessen, M.T., Whalen, J., Buguth, B.S. et al. Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. Respir Res 20, 18 (2019). https://doi.org/10.1186/s12931-019-0985-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12931-019-0985-2

Respiratory Research

ISSN: 1465-993X

Contact us